Liquidia Corporation

Biopharma company developing inhaled treprostinil therapies for rare lung diseases

What Liquidia does

Liquidia develops, manufactures and sells medicines for rare heart and lung diseases, especially pulmonary hypertension, a condition where blood pressure in the lungs' arteries is too high. Its main product, YUTREPIA, is an inhaled dry-powder form of the drug treprostinil. It also provides Remodulin, an injectable form of the same drug, and is testing L606, a slow-release inhaled version.

How Liquidia makes money

The company earns money by selling its treprostinil products, including YUTREPIA and Remodulin; Remodulin is sold under a promotion agreement with Sandoz. It develops new candidates such as L606 through licensing partnerships.

Products & services

• YUTREPIA (inhaled treprostinil dry powder)
• Remodulin (treprostinil injection)
• L606 (liposomal inhaled treprostinil, Phase III)
• PRINT particle engineering technology